**Directions on How to Fill Out the Annual WAC Report**

Manufacturers can either individually enter their products on the annual report page (step 7 in the user guide) OR upload and attach the approved Annual WAC Report template on the attachments page (step 8 in the user guide). ***\*Please do not manually enter products AND attach the approved template with the same products-this will result in duplicate entries in the system.\**** For the Annual WAC Report, the following information is required: manufacturer name, drug trade name, drug generic name, NDC#, drug type (generic or trade), price and price increase (yes or no-please see next). The remaining information is related to a price increase and is required by statute in HB 1033, Sec. 441.0053

*‘(b) If during a calendar year a prescription drug with a wholesale acquisition cost of at least $100 for a 30-day supply increases in price by 40 percent or more over the preceding three calendar years or 15 percent or more in the preceding calendar year in the wholesale acquisition cost of the prescription drug, the pharmaceutical drug manufacturer must include in the annual report submitted under Section 441.0051 the following information: (1) aggregate, company-level research and development costs for the most recent year for which final audit data is available; (2) the name of each of the manufacturer ’s prescription drugs approved by the United States Food and Drug Administration in the previous three calendar years; and (3) the name of each of the manufacturer ’s prescription drugs that lost patent exclusivity in the United States in the previous three calendar years.’*

If there is not a price increase meeting these criteria, you do not fill out the additional information. If there is, the following is required: drug FDA approved in the last three years (yes or no), drug lost patent exclusivity in the last three years (yes or no), price increase percentages (15% Increase in last calendar year or 40% increase in last three calendar years or N/A if neither or more), price increase related to research and development costs (yes or no), and any comments regarding price increase.